AKNETIDE® - Dermatologist Tested Anti-Acne Ingredient
Introducing AKNETIDE®
A Natural Antimicrobial Cyclopeptide
AKNETIDE® is a natural cyclopeptide that mimics host defense mechanisms, specifically targeting Cutibacterium acnes while regulating sebum oversecretion, alleviating inflammation, and expediting skin lesion repair — very gentle even to sensitive skin.
Key Insights from a global market Research*
Where to Start
About us
Pioneers in Natural Anti-Acne Solutions
Mission
At Dermatide Singapore, our mission is to invent & produce & deliver novel & efficacious & stable bioactive ingredients to empower individuals to achieve better beauty with confidence through science-backed and evidence-endorsed solutions.
Values
We are guided by a firm commitment to sustainability and nature, from natural ingredient discovery to the next-generation skincare technology development.
Our Team
Our Team are made up of industry experts, scientists, and thought leaders who guide us in shaping innovative, effective, and sustainable skincare solutions. Their insights and expertise help drive our commitment to excellence in every product we create.
Dr. Alain Khaiat
Scientific & Marketing Advisor
A leading expert in cosmetic science and product development with over 40 years of global experience. He has held senior R&D and Quality Assurance roles at Johnson & Johnson, Yves Rocher, and Revlon, and founded Seers Consulting in 2006 to advise the cosmetics industry worldwide. He is Chairman of CTFAS, former Chairman of ISO TC 217, and a recipient of the in-cosmetics Lifetime Achievement Award and APAC Beauty Industry Award.
Dr. Wang Jinfang
Sr. Scientific Advisor
A leading expert in cosmetic science and product development with over 40 years of global experience. He has held senior R&D and Quality Assurance roles at Johnson & Johnson, Yves Rocher, and Revlon, and founded Seers Consulting in 2006 to advise the cosmetics industry worldwide. He is Chairman of CTFAS, former Chairman of ISO TC 217, and a recipient of the in-cosmetics Lifetime Achievement Award and APAC Beauty Industry Award.
He used to work at Unilever China for 20 years since 2005, ever positioned as Principal Research Scientist and R&D Personal Care Director.
Robin Yao
President
MBA and MSc degrees. 10 years’ experiences in venture capital investment focusing on global biotech innovations, and 5 years’ experiences in corporate investment also focused on global biotech business. Co-founder of Planet Bioscience Pte Ltd in Singapore.
Prof. Xuejun Wen
Scientific Advisor
Fellow of the American Institute for Medical and Biological Engineering (AIMBE) and the National Academy of Inventors (NAI); founder of NOVIS Anti-Aging Technology, and William H. Goodwin Endowed Chair Professor at Virginia Commonwealth University. A leading expert in 3D bioprinting, biomaterials, stem cell technology, and regenerative medicine, he has developed 89 pioneering technologies and innovations, including antimicrobial biomaterials, stem cell culture peptides, injectable hydrogels, and 3D-printed tissue-engineered implants. His research has driven significant advances in biomedical engineering and translational medicine.
OUR FOOTPRINTS
NYSCC Suppliers' Day 2026 in New York
Dermatide Biotec made its debut at NYSCC Suppliers’ Day 2026 in New York City last week — and we left with something far more valuable than business cards: validation from the market that rigorous science still commands attention.
We brought one thing to the Javits Center: data. Two independent clinical studies. Five mechanistically validated modes of action. A double-blind trial. Instrumental measurements across papule count, acne volume, TEWL, sebum output, porphyrin area, and erythema. All from AKNETIDE® — the world’s first fermentation-derived antimicrobial cyclopeptide for blemish-prone skin, born out of Singapore.
The response from leading North American and global specialty ingredient distributors — including conversations that have been years in the making — confirmed what we have always believed: in a market saturated with claims, a compound that simply performs will always find its audience.
We are particularly grateful for the quality of engagement from distributors spanning the US, Latin America, and beyond — partners who understand that the next generation of cosmetic bioactives will not come from incremental reformulation, but from genuine biotechnology breakthroughs in fermentation science and antimicrobial peptide engineering.
Dermatide Biotech Showcases AKNETIDE® at In-Cosmetics Global 2026, Secures Strong European Partnerships
Paris, France – April 2026 – Following a highly successful exhibition at In-Cosmetics Global 2026 in Paris, we are thrilled to announce a significant milestone in our international expansion. Our proprietary antimicrobial cyclopeptide, AKNETIDE, captured substantial attention from leading European distribution partners, validating our commitment to deep tech, science-backed personal care innovations.
Throughout the event, our team had the opportunity to present the robust scientific dataset behind AKNETIDE. The strong reception from industry leaders was driven by our comprehensive, placebo-controlled clinical study results, which clearly demonstrate the peptide’s targeted efficacy and safety profile in anti-acne applications.
As a biotechnology innovator focused on next-generation bioactive molecules, we understand that modern personal care formulators demand not just novel ingredients, but irrefutable clinical evidence. The overwhelming interest from influential European distributors confirms that AKNETIDE’s rigorous R&D foundation—stemming from our specialized focus on high-performance molecules—is exactly what the global market is seeking.
We are currently advancing discussions with several key European partners to establish a strong distribution network across the EU. These strategic alliances will be instrumental in bringing our advanced biomolecular solutions to a wider audience, empowering formulators to create highly effective, scientifically validated skincare products.
Stay tuned for more updates as we finalize these partnerships and continue to push the boundaries of biotechnology in personal care.
PCHi 2026
🌟 What an extraordinary debut at PCHi 2026 in Hangzhou, China!
Dermatide Biotec, together with our trusted China representative, had an incredible three days last week connecting with the global beauty and personal care community. Hundreds of visitors from across the US, EU, Japan, South Korea, Thailand, Vietnam and beyond stopped by our booth — and the conversations were everything we could have hoped for: curious, technical, and genuinely energized.
The spotlight? AKNETIDE®— the world’s NOVEL antimicrobial cyclopeptide derived from Bacillus fermentation, purpose-built for cosmetic acne care. The interest from formulators and ingredient professionals around our 4-in-1 multi-mechanism active was deeply encouraging. And we had more than a few exciting conversations about what’s coming next in our R&D pipeline — bioactive peptides with broader personal care applications that we can’t wait to share in the months ahead.
To every visitor, conversation partner, and connector at PCHi — thank you. This is exactly why we show up. Here’s to a thriving Year of the Horse 🐎 and to building something remarkable together in 2026!
Look forward to meeting friends at In-Cosmetic Global in Paris in April.
In-Cosmetics Global 2025
We were delighted to attend in-cosmetics Global 2025 in Amsterdam, the Netherlands where we first ever introduced our innovative cosmetic ingredient — AKNETIDE®. As a world first-in-class Anti-acne Antimicrobial Cyclopeptide designed for efficient acne care, AKNETIDE® attracted strong interest from industry professionals, distributors & formulators, and brand developers.
In-Cosmetics Asia 2025
We had the pleasure of attending the In-Cosmetic Asia 2025 Expo in-cosmetics Asia in Bangkok. Our product, AKNETIDE®, garnered significant attention from global key distributors’ innovation leaders due to its solid and comprehensive technical dataset to tell a clear and convincing fact-based story how this first-in-class AKNETIDE® is able to be incredibly efficaciously against acne care but still so gentle to skin types, including in-vitro efficacy,clinical studies, in-vitro mechanism study including gene regulation analysis and in-vitro safety study.
In-Cosmetics Global 2025
We were delighted to attend in-cosmetics Global 2025 in Amsterdam, the Netherlands where we first ever introduced our innovative cosmetic ingredient — AKNETIDE®. As a world first-in-class Anti-acne Antimicrobial Cyclopeptide designed for efficient acne care, AKNETIDE® attracted strong interest from industry professionals, distributors & formulators, and brand developers.
In-Cosmetics Global 2025
We had the pleasure of attending the In-Cosmetic Asia 2025 Expo in-cosmetics Asia in Bangkok. Our product, AKNETIDE®, garnered significant attention from global key distributors’ innovation leaders due to its solid and comprehensive technical dataset to tell a clear and convincing fact-based story how this first-in-class AKNETIDE® is able to be incredibly efficaciously against acne care but still so gentle to skin types, including in-vitro efficacy,clinical studies, in-vitro mechanism study including gene regulation analysis and in-vitro safety study.